SMMTSummit TherapeuticsSigning up patients
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Non-Small Cell Lung Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 780 (planned)
- Started
- Feb 27, 2025
- Main results expected
- Apr 2028
- Fully finished
- Jun 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Survival (OS)
Measured over: Up to approximately 36 months
Progression free survival (PFS)
Measured over: Up to approximately 36 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06767514 · record last updated 2026-09-18 · checked 2026-11-09 15:47 UTC